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Abstract: Recently, we developed novel chiral dendrimer-triamine-coordinated Gd-MRI contrast
agents (Gd-MRI CAs), which showed longitudinal relaxivity (r1) values about four times higher than
that of clinically used Gd-DTPA (Magnevistr, Bayer). In our continuing study of pharmacokinetic
differences derived from both the chirality and generation of Gd-MRI CAs, we found that the
ability of chiral dendrimer Gd-MRI CAs to circulate within the body can be directly evaluated by
in vitro MRI (7 T). In this study, the association constants (Ka) of chiral dendrimer Gd-MRI CAs to
bovine serum albumin (BSA), measured and calculated with a quartz crystal microbalance (QCM)
in vitro, were found to be an extremely easy means for evaluating the body-circulation ability of
chiral dendrimer Gd-MRI CAs. The Ka values of S-isomeric dendrimer Gd-MRI CAs were generally
greater than those of R-isomeric dendrimer Gd-MRI CAs, which is consistent with the results of our
previous MRI study in vivo.
Keywords: chiral dendrimer; gadolinium; contrast agent; magnetic resonance imaging (MRI);
quartz crystal microbalance (QCM); association constant (Ka)
1. Introduction
Magnetic resonance imaging (MRI) is one of the most important non-invasive imaging modalities
for disease diagnosis, and there has been dramatic progress in this field over the past 30 years [1–3]. Particularly,
for the early and accurate diagnosis of tumors, low-molecular-weight gadolinium MRI contrast
agents (Gd-MRI CAs), such as Gd-DTPA (DTPA = diethylenetriaminepentaacetic acid) and Gd-DOTA
(DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), are widely used clinically to
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obtain clear and high-contrast MR images [4–10]. Unfortunately, the non-specific retention and rapid
clearance of low-molecular-weight Gd-MRI CAs generally require a high dosage (ca. 0.50 mol/L) of
these Gd-MRI CAs, which imposes a great physical strain and may lead to side effects in the patient,
such as osmotic shock [11,12] and nephrogenic systemic fibrosis (NSF) [13–15]. The main reason for
such a high dosage is that up to eight of the nine coordination sites of Gd are firmly occupied by ionic
chelating ligands, and only one site remains available for coordination with free water molecules,
which can be observed by MRI. In addition, Gd could show fast rotational motion at the center of
small ligands, and the image contrast is not high, which requires low-molecular-weight Gd-MRI
CAs. Therefore, there is a strong need for the development of highly sensitive Gd-MRI CAs.
Recently, there has been growing worldwide interest in the development of highly sensitive
Gd-MRI CAs that consist of Gd-functionalized dendrimers or other macromolecules [16–19].
Dendrimers [20–22] belong to a unique category of macromolecules with well-controlled sizes,
nanoscopic dimensions, and many peripheral chemical groups to which Gd chelates can be
coupled. As expected, Gd-functionalized poly(amidoamine) dendrimers (PAMAM) [23–26] and
poly(propyleneimine) dendrimers (PPI) [27–29] have been synthesized and evaluated both in vitro
and in vivo to achieve high-resolution MRI images, in which dendrimers were used as a core and Gd
chelates are positioned in the periphery [30]. In the Gd-functionalized dendrimers that have been
reported so far for use as MRI CAs, however, dendrimers were only used to slow the molecular
tumbling and the rotation of Gd center. While the duration of intravascular retention is prolonged,
the principle of reducing the 1H relaxation time of a water molecule is the same as that with
low-molecular-weight Gd-MRI CAs.
We previously reported the synthesis and functional evaluation of 2nd-generation chiral
dendrimer-triamine-coordinated Gd complexes with polyol end-groups as a highly sensitive MRI
CAs (Figure 1) [31,32]. More recently, we succeeded in the synthesis of chiral dendrimer-triamine-
coordinated Gd-MRI CAs with aminoalcohol end-groups, and the large difference in the
pharmacokinetics of the optical isomers, 2-(R) and 2-(S), was clarified. The synthesized Gd-MRI
CAs were shown to have longitudinal relaxivity (r1) three times higher than that of clinically used
Gd-DTPA. In addition, the pharmacokinetic difference between optical isomers could be easily and
precisely evaluated by T1-weighted in vivo MRI of mice before and after the intravenous injection
of 2-(R) and 2-(S), respectively. As a result, 2-(S) is retained in the vasculature for a longer time
after administration.
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Figure 1. Structure of 2nd-generation chiral dendrimer-triamine-coordinated Gd-MRI CA with 
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Figure 1. Structure of 2nd-generation chiral dendrimer-triamine-coordinated Gd-MRI CA with polyol
end-groups, 2-(R).
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In this study, we found that the pharmacokinetic difference derived from both the chirality and
the generation of chiral dendrimer Gd-MRI CAs can be evaluated by in vivo MRI and estimated
by in vitro QCM. These results are consistent with each other. First, 2nd- and 3rd-generation chiral
dendrimer-triamine-coordinated CAs, 2-(R), 2-(S), 3-(R), and 3-(S), were synthesized. As an index for
evaluating the body circulation ability of these chiral dendrimer Gd-MRI CAs, association constants
(Ka) with plasma protein were calculated by a quartz crystal microbalance (QCM) measurement.
QCM can measure a change in weight based on the fact that the resonant frequency of a quartz
crystal decreases with an increase in its mass due to the adhesion of a substrate on the quartz
surface [33]. While the exact amount of the substrate that adhered to the quartz surface can be
calculated using the Sauebrey equation [34], the association constant (Ka) of our synthesized chiral
dendrimer Gd-MRI CAs with bovine serum albumin (BSA), which is a model of plasma protein, was




All reagents were used without further purification unless otherwise noted. PPh3 (97.0%),
N-bromosuccinimide (NBS, 99.9%), Ce(NH4)2(NO3)6 (CAN, 95%), GdCl3.6H2O, KOH (85%),
K2CO3 (99.5%), MgSO4 (99.0%), NaHCO3 (99.5%), Na2CO3 (99.8%), Na2SO3 (97.0%), Na2SO4
(99.0%), CH3CN (99.8%), CHCl3 (99.9%), hexane (99%), methanol (MeOH; 99.8%), acetone (99%),
tetrahydrofuran (THF), distilled water, acetic acid, and BSA were purchased from Nacalai Tesque Inc.
(Kyoto, Japan). 1.0 mol/L Lithium ethoxide in tetrahydrofuran was purchased from Sigma-Aldrich
Japan K. K. (Tokyo, Japan). 1,4,7-Triazacyclononane (TACN, 98%) was purchased from Tokyo
Chemical Industry Co. Ltd. (Tokyo, Japan). Methylene chloride (CH2Cl2) was purchased from
Kishida Chemical Co., Ltd. (Osaka, Japan). Gd-DTPA (gadopentetate meglumine; Magnevistr)
was purchased from Bayer Holding Ltd. (Tokyo, Japan), and used as a control for all MRI
measurements. Aluminum oxide 90 (activity neutral) was purchased from Merck Chemical Inc.
(Darmstadt, Germany). Silica gel 60N spherical for flash chromatography was purchased from Kanto
Chemical Co. Inc. (Tokyo, Japan). Filter-Aid Celite Standard Super-gel was purchased from Alfa
Aesar (Lancaster, UK).
1H-NMR spectra were recorded at 400 MHz and 13C-NMR spectra were recorded at 100 MHz
with a JEOL EX400 (JEOL Inc., Tokyo, Japan). ESI-TOF mass spectra were obtained by a micrOTOF
focus (Bruker Daltonics Co., Billerica, MA, USA). Specific optical rotations were measured by a P-2100
polarimeter (JASCO, Tokyo, Japan). The concentration of gadolinium was determined by polarized
Zeeman atomic absorption spectrometry (AAS; Z-2710, Hitachi Ltd., Tokyo, Japan) with a hollow
cathode lamp (422.58 nm; L233-64NB; Hamamatsu Photonics K. K., Hamamatsu, Japan) using
a gadolinium standard solution (1000 ppm, analytical grade, Wako, Japan).
2.2. Synthesis of 3rd-Generation Chiral Dendrimer-Triamine-Coordinated Gd-MRI CAs (Scheme 1)
2.2.1. 2nd-Generation Chiral Dendron with Polyol End-Groups 6
A solution of 5 (17.0 g, 26.0 mmol) [32] in 3 N HCl (100 mL) and CH3CN (200 mL) was stirred at
room temperature for 4 h. The product was concentrated under vacuum, and the residue was filtered.
The filtered product was washed with CH3CN to remove the residual volatiles. The filtrate was
concentrated again under vacuum, filtered, and washed with CH3CN. The crude product collected
was purified by recrystallization (ethyl acetate) to give 6 as a white solid (12.5 g, 45.6 mmol). 1H-NMR
(CD3OD), δ (ppm): 3.52–3.60 (m, 5H); 3.68–3.71 (m, 4H); 4.34, 4.37 (d, 1H); 4.46–4.69 (m, 6H); 5.00
(s, 2H); 6.80–6.91 (m, 4H); 7.22–7.43 (m, 12H). 13C-NMR (CD3OD), δ (ppm): 56.1, 68.7, 71.4, 71.6,
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74.0, 75.6, 75.7, 81.5, 115.7, 117.0, 127.4, 128.4, 128.8, 128.9, 138.8, 138.9, 140.1, 142.8, 154.3, 155.5.
ESI-TOF-MS: m/z [M + H]+ calcd. for 603.7320, found 603.7352.
2.2.2. 3rd-Generation Chiral Dendron with Polyacetonide End-Group 7
To a 200 mL Pyrex flask equipped with a Dean-Stark apparatus and a reflux condenser were
added 6 (2.5 g, 4.4 mmol), 5 (4.5 g, 19.7 mmol), and toluene (50 mL) in this order under a flow of argon.
The mixture was heated with stirring for about 30 min to make a uniform solution. To the resulting
uniform solution was added KOH pellets (2.0 g) to give a cloudy orange solution. The mixture was
then heated under reflux for 12 h. After the reaction was complete (checked by TLC), the resulting
solution was concentrated under vacuum, and an orange crude product with high viscosity was
obtained. The crude product was dissolved in methylene chloride, and ethyl acetate and hexane
were then added and suction filtration gave a uniform orange solution. The solvent was removed
under vacuum, and the residue was purified by flash column chromatography (neutral Al2O3, ethyl
acetate - hexane = gradient from 1:1 to 1:0) to give 7 (3.3 g, 2.5 mmol) as a yellow solid. 1H-NMR
(CDCl3), δ (ppm): 1.48, 1.54 (d, 24H); 3.52–3.78 (m, 13H); 4.26–4.30 (q, 4H); 4.34–4.35 (d, 3H); 4.38–4.68
(m, 12H); 5.01–5.07(m, 6H), 6.83–6.93 (m, 4H); 7.26–7.45 (m, 28H). 13C-NMR (CDCl3), δ (ppm): 26.0,
26.6, 55.7, 70.3, 71.7, 73.0, 74.8, 77.8, 80.2, 109.7, 114.7, 115.8, 126.2, 127.1, 127.7, 127.9, 138.2, 138.3,
138.4, 138.5, 156.4, 157.3. ESI-TOF-MS: m/z [M + Na]+ calcd. for 1357.6440, found 1357.6463.
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Scheme 1. Synthesis of 3rd-generation chiral dendrimer-triamine-coordinated Gd complexes, 3-(R)
and 3-(S).
2.2.3. 3rd- eneration Chiral endron 8 fro 7 by eprotection
solution of 7 (1.47 g, 1.05 ol) in C C (50 L) as stirred at ´10 ˝C, and a solution of
C (1.15 g, 2.10 ol) in water (25 mL) was added dropwise. After the addition was complete, the
resulting mixture was stirred for 30 min and then cooled to 0 ˝C, followed by the addition of water
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(150 mL). The resulting mixture was transferred to a separating funnel, and after extraction with ethyl
acetate and water, the water layer was extracted three times with ethyl acetate. The organic layer was
collected and washed twice with a 5% K2CO3 aqueous solution. The organic layer was combined
and washed with a 10% Na2SO3 aqueous solution and 5% K2CO3 aqueous solution. The organic
layers were then washed with brine and dried over MgSO4, followed by concentration under vacuum.
The crude product was purified by column chromatography (SiO2, ethyl acetate-hexane = gradient
from 1:1 to 100:0) to give 8 (1.028 g, 837 µmol, 80%) as an orange solid. 1H-NMR (CDCl3), δ (ppm):
1.48, 1.54 (d, 24H); 3.52–3.80 (m, 10H); 4.26–4.28 (m, 4H); 4.30–4.68 (m, 17H); 5.04–5.07 (m, 4H);
7.26–7.36 (m, 28H). 13C-NMR (CDCl3), δ (ppm): 26.0, 26.6, 65.0, 70.3, 71.6, 73.0, 74.8, 77.8, 80.2, 109.7,
126.2, 127.1, 127.7, 127.9, 138.2, 138.3, 138.4, 138.5. ESI TOF MS: m/z [M + Na]+ calcd. for 1251.6021,
found 1251.5840.
2.2.4. 3rd-Generation Chiral Dendron 9 from 8 by Bromination
8 (1.03 g, 837 µmol) and methylene chloride (20 mL) were added to a 100 mL Pyrex flask under
a flow of argon. The flask was immersed in a cooling bath, and at 0 ˝C, PPh3 (235 mg, 902 µmol) and
NBS (170 mg, 955 µmol) were added together under a flow of argon. The mixture was stirred for 2 h
at 0 ˝C. After the reaction was complete (checked by TLC), to the reaction mixture were added diethyl
ether (10 mL) and saturated Na2CO3 aqueous solution (10 mL). After the solution was separated,
the organic layer was washed with brine and dried over MgSO4. The resulting organic layer was
concentrated under vacuum, and the residue was purified by column chromatography (SiO2, ethyl
acetate-hexane = gradient from 3:1 to 1:1) to give 9 as a white solid (320 mg, 248 µmol, 30%). 1H-NMR
(CDCl3), δ (ppm): 1.47, 1.54 (d, 24H); 3.52–3.73 (m, 10H); 4.25–4.29 (m, 4H); 4.32–4.71 (m, 17H);
5.02–5.07 (m, 4H); 7.22–7.38 (m, 28H). 13C-NMR (CDCl3), δ (ppm): 25.8, 26.4, 33.1, 67.7, 70.3, 71.4,
72.8, 74.2, 77.6, 80.0, 109.5, 125.9, 126.1, 127.3, 127.7, 138.2, 138.3, 138.4, 138.5. ESI-TOF-MS: m/z [M + H]+
calcd. for 1313.5177, found 1313.5186.
2.2.5. 3rd-Generation Chiral Dendrimer with Polyacetonide End-Group 10
A solution of LiOEt in THF (1.0 mol/L, 5.0 mL) was added dropwise to a solution of TACN
(10.0 mg, 80.0 µmol) in THF (20 mL), and the mixture was stirred at 0 ˝C under an argon atmosphere.
After 10 min, 9 (320 mg, 247 µmol) was added dropwise at 0 ˝C, and the mixture was stirred at room
temperature for 12 h. The mixture was then diluted by the addition of ethyl acetate (40 mL), and
dried over MgSO4. The solvent was removed under reduced pressure, and the residue was purified
by flash column chromatography (SiO2, CHCl3:MeOH = 20:1) to give 65.0 mg (17.3 µmol, 22%) of
10. 1H-NMR (CDCl3), δ (ppm): 1.40, 1.46 (s, 72H); 2.77 (br, 12H); 3.44–3.66 (m, 36H); 4.18–4.22 (t,
12H); 4.27–4.59 (m, 45H); 4.96–4.99 (t, 12H); 7.18–7.24 (m, 84H). 13C-NMR (CDCl3), δ (ppm): 25.9,
26.6, 55.0, 70.3, 71.6, 73.0, 73.2, 74.8, 77.7, 80.4, 109.6, 126.2, 127.1, 127.7, 127.8, 138.1, 138.2, 138.3, 138.4.
ESI-TOF-MS: m/z [M + H]+ calcd. for 3764.7120, found 3764.8410.
2.2.6. 3rd-Generation Chiral Dendrimer with Polyol End-Group 11
10 (60.0 mg, 16 µmol) was dissolved and stirred in 80% acetic acid/water (5.0 mL) at room
temperature for 6 h, the reaction was monitored by ESI-TOF MS. After the reaction was complete, the
solvent was removed under reduced pressure to give 42 mg (13 µmol, 81%) of 11. 1H-NMR (CD3OD),
δ (ppm): 2.82 (br, 12H); 3.54–3.72 (m, 36H); 4.31–4.44 (m, 57H); 4.62–4.64 (m, 12H); 7.14–7.27 (m, 84H).
13C-NMR (CD3OD), δ (ppm): 50.2, 60.6, 68.7, 71.8, 74.0, 75.3, 75.6, 81.4, 127.4, 128.6, 128.7, 131.6, 136.1,
138.7, 141.6, 142.7. ESI-TOF-MS: m/z [M + H]+ calcd. for 3283.9320, found 3283.9919.
2.2.7. 3rd-Generation Chiral Dendrimer-Triamine-Coordinated Gadolinium Complex 3
A solution of GdCl3¨ 6H2O (4.8 mg, 12.9 µmol) in MeOH (5.0 mL) was added dropwise to
a solution of 11 (42.0 mg, 12.8 µmol) in MeOH (5.0 mL), and the mixture was stirred at room
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temperature for 24 h. The solvent was removed under reduced pressure to give 45.0 mg (12.7 µmol)
of 3 as a white solid.
2.3. Relaxation Time Measurements
Longitudinal relaxivity (r1) was calculated from the T1-relaxation time of water proton
measured under four different concentrations (0.50, 0.25, 0.10, 0 mmol/L) of Gd-MRI CAs at
20 ˝C with a Biospec 7.0 T/20 USR (Bruker Biospin Inc., Billerica, MA, USA) and a 72 mm i.d.
Quadrature resonator.
2.4. Cytotoxicity Assay
Murine L929 fibroblast cells were placed in each well of 96-multiwell cell culture plates (Corning
Inc., Lowell, MA, USA) with growth medium (Dulbecco’s modified minimum essential medium
(DMEM); Life Technologies Japan Ltd., Tokyo, Japan) containing 10% of fetal bovine serum (FBS;
Sanko Pure Chemical Co., Tokyo, Japan), 100 mg/mL of penicillin and 0.10 mg/mL of streptomycin
(Sigma-Aldrich Japan K.K., Tokyo, Japan) at a density of 1 ˆ 104 cells/cm2. After incubation for
24 h at 37 ˝C and 5% CO2/95% air at atmospheric pressure, the medium was replaced by fresh
growth medium containing 0.25 mmol/L of Gd-MRI CAs. After incubation for 48 h under the same
conditions, the cell number was evaluated. After Cell Count Reagent SF (10 µL, Nacalai Tesque,
Kyoto, Japan) was added to each well, plates were incubated for 60 min under the same conditions.
The absorbance at 450 nm was then measured by a spectrophotometer (Versa max, Molecular Devices
Inc., Union City, CA, USA). The absorbance was normalized by that in cells incubated with growth
medium without Gd-MRI CAs and expressed as a cell viability ratio.
2.5. Quartz Crystal Microbalance (Affinix-Qr) Analysis
The ability of Gd-MRI CAs to interact with bovine serum albumin (BSA) as a model protein of
blood plasma was evaluated with a quartz crystal microbalance system (Affinix-Qr, Initium Inc.,
Tokyo, Japan). Briefly, 5 µL of a mixture of H2SO4 and H2O2 (3:1, called as piranha solution) was
mounted to the Au surface (5.7 mm2) on the quartz crystal sensor, and incubated for 5 min at room
temperature. The sensor was then washed thoroughly with double-distilled water, and the washing
was repeated three times. After the sensor was dried, the frequency of the quartz sensor was recorded
in air and in water at 25 ˝C with stirring at 600 rpm, where the drift of the sensor was kept below
3.0 Hz/min. Next, 2.0 µL of BSA solution (100 µg/mL in water) was applied to the sensor and
BSA immobilization was performed for 15 min with incubation at room temperature under saturated
humidity. After the immobilized-BSA sensor was washed with water three times, it was immersed in
a batch cell with 8.0 mL water. The amount of immobilized-BSA was calculated from the change in
frequency before and after immobilization. A corresponding amount of sample was dissolved with
8.0 µL of water, and injected into the batch cell. Changes in frequency were recorded point by point
until the adsorption was saturated. The dissociation rate constant (Kd) was estimated using AQUA
software (Initium Inc., Tokyo, Japan) by a global fitting analysis of the saturated adsorption amount
at each concentration, and the association rate constant (Ka) was calculated as 1/Kd.
2.6. Evaluation of the Body Distribution of Chiral Dendrimer Gd-MRI CAs by in Vivo MRI
All the animal experiments were performed according to the Institutional Guidelines of Kyoto
University on Animal Experimentation and with permission from the Animal Experiment Committee
of the Faculty of Medicine, Kyoto University. Chiral dendrimer Gd-MRI CAs were injected into
the tail vein of ddY mice (6 or 8 weeks old, Shimizu Laboratory Supplies, Co. Ltd., Kyoto, Japan)
intravenously. The time course of distribution of chiral dendrimer Gd-MRI CAs in a mouse body
was evaluated by obtaining T1-weighted MR images before and after injection. To evaluate the
pharmacokinetics of chiral dendrimer Gd-MRI CAs, mice were laparotomized at 30 min and 60 min
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after the administration of chiral dendrimer Gd-MRI CAs (0.10 mmol Gd/kg) to collect blood from
the heart, and the concentration of gadolinium in blood was determined with AAS (n = 3). The total
amount of chiral dendrimer Gd-MRI CAs in blood was estimated from the volume of total blood
(78.0 mL/kg). After blood collection, the liver and kidney of the mice were minced with scissors,
and gadolinium in the tissues was extracted with 5.0 mL of 1.0 mol/L HNO3 aq. After filtration
(Millipore Millexr LG 0.20 µm; Merck KGaA, Darmstadt, Germany), the gadolinium concentration
in these filtrates was determined with AAS, and the total amount of chiral dendrimer Gd-MRI CAs in
liver and kidney was estimated from the weight of the tissues. In addition, urine was collected from
mice at 60 min after the injection of chiral dendrimer Gd-MRI CAs, and the gadolinium content was
determined by AAS after dilution with 1.0 mol/L HNO3 aq. and filtration (n = 3; each sample was
gathered from three mice).
3. Results and Discussion
3.1. Synthesis of 2nd- and 3rd-Generation Chiral Dendrimer-Triamine-Coordinated Gd-MRI CAs
2nd-generation chiral dendrimer-triamine-coordinated Gd complexes, 2-(R) and 2-(S), were
synthesized according to our reported method [31]. As shown in Scheme 1, 3rd-generation chiral
dendrimer-triamine-coordinated Gd complexes, 3-(R) and 3-(S), were synthesized from 5 through the
repeated protection/deprotection of chiral 1,2-diol groups and a benzylic bromide to be connected to
a triamine core.
3.2. Functional Evaluation of Chiral Dendrimer-Triamine-Coordinated Gd Complexes, 2-(R), 2-(S), 3-(R),
and 3-(S), as Highly Sensitive MRI Contrast Agents
3.2.1. Functional Evaluation of Chiral Dendrimer Gd Complexes by in Vitro MRI
The longitudinal relaxivity values (r1) of new chiral dendrimer Gd complexes as well as
Gd-DTPA were measured (Figure 2, Table 1). The r1 values of 2-(R) and 2-(S) (2nd-generation) were
11.4 and 11.1 (mmol/L)´1¨ s´1, respectively, which were approximately 2.5 times larger than that
of the clinically used Gd-DTPA. In addition, the r1 values of 3-(R) and 3-(S) (3rd-generation) were
16.3 and 16.4 (mmol/L)´1¨ s´1, respectively, which were approximately 3.6 times larger than that of
Gd-DTPA. These results indicate that the r1 values of the Gd complexes increased as the size and
the generation of chiral dendrimer ligands increased (Table 1). This can be explained by both the
approach and coordination of many water molecules to a gadolinium center through the hydrogen
bonding with polyol end-groups in chiral dendrimer Gd complexes, which are more prevalent in
bigger dendrimers. Consequently, all of these chiral dendrimer Gd complexes, 2-(R), 2-(S), 3-(R), and
3-(S), are highly efficient MRI contrast agents.
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Figure 2. T1-weighted MR images of Gd-DTPA, GdCl3.6H2O, 2-(R), 2-(S), 3-(R), 3-(S), (0.25 mmol/L) 
and water (Spin echo from TR/TE 200/6.2 ms, 7 T, 20 °C). 





Figure 2. T1-weighted MR images of Gd-DTPA, GdCl3.6H2O, 2-(R), 2-(S), 3-(R), 3-(S), (0.25 mmol/L)
and water (Spin echo from TR/TE 200/6.2 ms, 7 T, 20 ˝C).
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Table 1. Longitudinal relaxivities (r1) of Gd-DTPA, 2-(R), 2-(S), 3-(R) and 3-(S).






3.2.2. Cytotoxicity of Chiral Dendrimer Gd-MRI CAs
The cytotoxicities of 2-(R), 2-(S), 3-(R), 3-(S), GdCl3¨ 6H2O, and Gd-DTPA are summarized in
Figure 3. There were no obvious differences in cell viability between chiral dendrimer Gd-MRI
CAs and Gd-DTPA, even at a high concentration of up to 0.25 mmol/L. Only GdCl3¨ 6H2O showed
cytotoxicity at 0.25 mmol/L. Thus, chiral dendrimer Gd-MRI CAs have low toxicity with excellent
size- and molecular-weight-dependent sensitivity, suitable for obtaining high-contrast MR images.
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Figure 3. Viabilities of L929 cells 24 h after incubation with Gd-DTPA, GdCl3.6H2O, 2-(R), 2-(S), 3-(R) 
and 3-(S) (0.25 mmol/L). 
3.2.3. Functional Evaluation and Pharmacokinetics of Chiral Dendrimer Gd-MRI CAs by in Vivo 
MRI 
Contrast enhancement after the administration of chiral dendrimer Gd-MRI CAs (2-(R), 2-(S),  
3-(R), and 3-(S)) as well as Gd-DTPA was evaluated by in vivo MRI. Figure 4 shows T1-weighted MR 
images of mice before and after intravenous injection of the Gd-MRI CAs, where the dose  
(0.10 mmol Gd/kg) was determined with reference to that of clinically used Gd-DTPA. 
 
Figure 4. T1-weighted MR images of mice after intravenous injection of Gd-DTPA, 2-(R), 2-(S), 3-(R) 
and 3-(S) (0.10 mmol Gd/kg). 
Figure 3. Viabilities of L929 cells 24 h after incubation with Gd-DTPA, GdCl3.6H2O, 2-(R), 2-(S), 3-(R)
and 3-(S) (0.25 m ol/L).
3.2.3. Functional Evaluation and Pharmacokinetics of Chiral Dendrimer Gd-MRI CAs by in Vivo MRI
Contrast enhancement after the ad i i iral dendrimer Gd-MRI CAs (2-(R), 2-(S),
3-(R), and 3-(S)) as ll d-DTPA was evaluated by in vivo MRI. Figure 4 hows T1-weighted
MR images of mice before and after intravenous injection of the Gd-MRI CAs, where the dose
(0.10 m ol Gd/kg) was deter ined ith reference to that of clinically used Gd-DTPA.
After the injection of Gd-DTPA, most Gd-DTPA was excreted through the kidneys within 30 min,
and accumulated in the bladder, while little contrast enhancement was observed except for the
kidneys. In sharp contrast, after the injection of 2nd-generation chiral dendrimer Gd-MRI CAs,
2-(R) and 2-(S), no accumulation was observed in specific organs such as the liver and kidney.
In comparison to Gd-DTPA, 2-(R) and 2-(S) should be suitable for magnetic resonance angiography
(MRA) because they are retained in the blood for a long duration. There was no obvious difference in
the body distributions of 2-(R) and 2-(S).
Similarly, after the injection of 3-(R) and 3-(S), no accumulation was observed in specific organs
such as the liver and kidney. The most important difference between 3-(R) and 3-(S) was that 3-(S)
provided greater contrast enhancement than 3-(R), when evaluated 30 min after injection. In addition,
3-(R) and 3-(S) provided much greater contrast enhancement than 2-(R) and 2-(S), which means that
the difference in contrast enhancement derived from the chirality in dendrimer ligands is highly
dependent on both the size and generation of chiral dendrimer ligands, judging from the r1 values
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(vide supra). No gadolinium accumulation was observed in the liver, kidney, or blood vessels within
48 h after the injection of the chiral dendrimer Gd-MRI CAs by AAS, which indicates that all of the
chiral dendrimer Gd-MRI CAs were completely excreted from the body.
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Figure 4. T1-weighted MR images of mice after intravenous injection of Gd-DTPA, 2-(R), 2-(S), 3-(R)
and 3-(S) (0.10 mmol Gd/kg).
The signal intensities of blood vessels and the distributions of all chiral dendrimer Gd-MRI CAs
in organs up to 3 h after administration were calculated based on the results shown in Figure 4.
In addition, Figure 5 shows that the retention times of all of the new chiral dendrimer Gd-MRI CAs
were greater than that of Gd-DTPA.
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After the injection of Gd-DTPA, most Gd-DTPA was excreted through the kidneys within  
30 min, and accumulated in the bladder, while little contrast enhancement was observed except for 
the kidneys. In sharp contrast, after the injection of 2nd-generation chiral dendrimer Gd-MRI CAs,  
2-(R) and 2-(S), no accumulation was observed in specific organs such as the liver and kidney.  
In comparison to Gd-DTPA, 2-(R) and 2-(S) should be suitable for magnetic resonance angiography 
(MRA) because they are retained in the blood for a long duration. There was no obvious difference 
in the body distributions of 2-(R) and 2-(S). 
Similarly, after the injection of 3-(R) and 3-(S), no accumulation was observed in specific 
organs such as the liver and kidney. The most important difference between 3-(R) and 3-(S) was 
that 3-(S) provided greater contrast enhancement than 3-(R), when evaluated 30 min after injection. 
In addition, 3-(R) and 3-(S) provided much greater contrast enhancement than 2-(R) and 2-(S), 
which means that the difference in contrast enhancement derived from the chirality in dendrimer 
ligands is highly dependent on both the size and generation of chiral dendrimer ligands, judging 
from the r1 values (vid  supra). No gadolinium accumulatio  was observed in the liver, kidney, or 
blood vessels within 48 h after the injection of the chiral dendrimer Gd-MRI CAs by AAS, which 
indicates that all of the chiral dendrimer Gd-MRI CAs were completely excreted from the body. 
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Figure 5. Post/pre signal intensity (SI) enhancement of mouse tissues after intravenous injection of 
Gd-DTPA, 2-(R), 2-(S), 3-(R) and 3-(S) (0.10 mmol Gd/kg). 
2-(S) is retained in blood vessels somewhat longer than 2-(R). Thus, 2-(S) would be superior to 
2-(R) in the circulation of a mouse without accumulation in specific organs, and should be suitable 
for detecting cancer tissues that contain many new blood vessels. The slight enhancement of 
contrast in the liver also supports this possibility since 2-(S) may show superior circulation in the 
liver which contains many blood vessels (Figure 4). 
As for 3rd-generation Gd-MRI CAs, the calculated signal intensities of blood vessels suggest 
that 3-(S) is retained in the blood vessels longer than 3-(R) (Figure 5). This means that 3-(S), rather 
than 3-(R), would have a long circulation time in mice without accumulation in specific organs, and 
would be suitable for detecting cancer tissues that contain many new blood vessels. 
The urine of mice was collected after the administration of chiral dendrimer Gd-MRI CAs 
(2-(R) and 2-(S), 3-(R), and 3-(S)), and the gadolinium contents in urine were quantified by AAS. In 
addition, the mice were sacrificed in 60 min after the administration, and the liver, kidney and 
Figure 5. Post/pre signal intensity (SI) enhancement of ouse tissues after intravenous injection of
d- TP , 2-( ), 2-(S), 3-( ) and 3-(S) (0.10 ol d/kg).
2-(S) is retained in blood vessels somewhat longer than 2-(R). Thus, 2-(S) would be superior to
2-(R) in the circulation of a mouse without accumulation in specific organs, and should be suitable
for detecting cancer tissues that contain many new blood vessels. The slight enhancement of contrast
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in the liver also supports this possibility since 2-(S) may show superior circulation in the liver which
contains many blood vessels (Figure 4).
As for 3rd-generation Gd-MRI CAs, the calculated signal intensities of blood vessels suggest that
3-(S) is retained in the blood vessels longer than 3-(R) (Figure 5). This means that 3-(S), rather than
3-(R), would have a long circulation time in mice without accumulation in specific organs, and would
be suitable for detecting cancer tissues that contain many new blood vessels.
The urine of mice was collected after the administration of chiral dendrimer Gd-MRI CAs
(2-(R) and 2-(S), 3-(R), and 3-(S)), and the gadolinium contents in urine were quantified by AAS.
In addition, the mice were sacrificed in 60 min after the administration, and the liver, kidney and
blood were collected and the concentrations of gadolinium in these organs and blood were analyzed
by AAS. Figure 6 shows the distribution of gadolinium in urine, liver, and blood at 60 min after
the administration of the new CAs. As can be readily seen from Figure 6, all of the new chiral
dendrimer Gd-MRI CAs were traced quantitatively, but there was no significant difference in the
pharmacokinetics of 2-(R) and 2-(S) at 60 min after injection.
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Figure 6. Body distribution of 2-(R), 2-(S), 3-(R) and 3-(S) 60 min after intravenous injection into mice 
(0.10 mmol Gd/kg). 
In addition, cumulative quantification of Gd3+ in urine by AAS clearly showed that Gd3+ in 
2-(R) and 2-(S) was completely excreted, respectively, without accumulation in the tissues and 
organs at 24 h after injection. If the chiral dendrimer-triamine ligands in 2-(R) and 2-(S) dissociate 
from Gd3+ (the circulating concentration of Gd3+ was estimated as ca. 1.27 mmol/L) and are 
transferred to free metals with coordination in the blood, such as Ca2+ (0.65 mM) and Mg2+  
(0.40 mmol/L) [35], the free Gd3+ without ligands easily forms GdPO4 which accumulates and 
remains in the bone, kidney, and liver. Accordingly, we consider that all novel chiral 
dendrimer-triamine-coordinated Gd CAs have enough stability to survive even in the blood 
containing free metal ions [36]. The cumulative assay of gadolinium in mouse urine after the 
administration of 3-(R) and 3-(S) clearly shows that 3-(R) is excreted in the urine faster than 3-(S). 
3.2.4. Affinity of Chiral Dendrimer Gd-MRI CAs with Plasma Protein Estimated by in Vitro Quartz 
Crystal Microbalance Measurement 
To estimate the difference in pharmacokinetics of chiral dendrimer Gd-MRI CAs, the 
interaction and affinity of chiral dendrimer Gd-MRI CAs with plasma proteins was measured by a 
quartz crystal microbalance (QCM) method. QCM makes it possible to measure a change in weight 
based on the fact that the resonant frequency of a quartz crystal decreases with an increase in its 
mass, which results from the adhesion of some substance to the quartz surface. The association 
constants (Ka) of chiral dendrimer Gd-MRI CAs with bovine serum albumin (BSA), which is a 
model of plasma proteins, were estimated from the change in mass for a quartz surface that was 
first covered with BSA and then subjected to the sequential addition of chiral dendrimer Gd-MRI 
CAs. From the change in mass (ΔF) and concentrations of added chiral dendrimer Gd-MRI CAs 
([CA]), the change in frequency under the saturated adhesion of chiral dendrimer Gd-MRI CAs 
(ΔFmax) can be estimated through a least squares approximation using Equation. The concentration 
of [CA] that would give half of ΔFmax under a change in mass could be assumed to be Ka−1: ∆ → ∆  
Based on the results in Figure 7 and Table 2, 2-(S) showed a Ka value that was about 57-fold 
higher than that of 2-(R). This means that 2-(S) is retained longer in the blood than 2-(R). Also, 3-(S) 
Figure 6. Body distribution of 2-(R), 2-(S), 3-(R) and 3-(S) 60 in after intravenous injection into ice
(0.10 mmol Gd/kg).
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at 24 h af er injection. If the chiral d ndrimer-triamine lig nds in 2-(R) and (S) dissociate from Gd3+
(the circulating con entration f Gd3+ was estimated as ca. 1.27 mmol/L) nd are transferred to fre
metals with c ordination in the blood, such as Ca2+ (0.65 mM) and Mg2+ (0.40 mmol/L) [35], the free
Gd3+ without ligands easily forms GdPO4 which accumu ates and remains in the bone, kidn y,
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enough stability to survive ev n in the blood containin free metal ions [36]. The cumulative assay
of g dolinium in mouse urine after the administration of 3-(R) and 3-(S) clearly hows that 3-(R) is
excreted in the urine faster than 3-(S).
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Crystal Microbalance Measurement
To estimate the difference in pharmacokinetics of chiral dendrimer Gd-MRI CAs, the interaction
and affinity of chiral dendrimer Gd-MRI CAs with plasma proteins was measured by a quartz crystal
microbalance (QCM) method. QCM makes it possible to measure a change in weight based on the fact
that the resonant frequency of a quartz crystal decreases with an increase in its mass, which results
from the adhesion of some substance to the quartz surface. The association constants (Ka) of chiral
dendrimer Gd-MRI CAs with bovine serum albumin (BSA), which is a model of plasma proteins,
were estimated from the change in mass for a quartz surface that was first covered with BSA and
then subjected to the sequential addition of chiral dendrimer Gd-MRI CAs. From the change in mass
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(∆F) and concentrations of added chiral dendrimer Gd-MRI CAs ([CA]), the change in frequency
under the saturated adhesion of chiral dendrimer Gd-MRI CAs (∆Fmax) can be estimated through
a least squares approximation using Equation. The concentration of [CA] that would give half of




Based on the results in Figure 7 and Table 2, 2-(S) showed a Ka value that was about 57-fold
higher than that of 2-(R). This means that 2-(S) is retained longer in the blood than 2-(R). Also, 3-(S)
showed about a Ka value that was about 19-fold higher than that of 3-(R). Although ∆F of 3-(R)
appeared to be greater than that of 3-(S) in Figure 7b, the Ka of 3-(S) was estimated to be higher than
that of 3-(R) by an approximation curve (Equation (1)). This means that 3-(S) is retained longer in the
blood than 3-(R). In addition, the reason why a large difference in Ka was observed for 3rd-generation
CAs (3-(R) and 3-(S)), but not 2nd-generation CAs (2-(R) and 2-(S)), is considered to be the increase
in the number of chiral centers, which leads to an increase in optical rotation. In fact, the number
of chiral centers in chiral dendrimer Gd-MRI CAs was increased from 9 (2-(R) and 2-(S)) to 21 (3-(R)
and 3-(S)).
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Figure 7. Frequency change of the Au electrodes on quartz crystals coated with BSA after addition of 
(a) 2-(R) (○) and 2-(S) (△); (b) 3-(R) (○) and 3-(S) (△). 
Table 2. Association constant (Ka) of synthesized CAs (2-(R), 2-(S), 3-(R) and 3-(S)) with bovine 
serum albumin (BSA). 
Sample Kd (mol/L) Ka (mol/L−1) ΔFmax
2-(R) 1.42 × 10−9 7.04 × 108 13.7 
2-(S) 2.49 × 10−11 4.02 × 1010 58.3 
3-(R) 1.02 × 10−9 9.80 × 108 969 
3-(S) 5.57 × 10−11 1.80 × 1010 83.8 
Generally, drugs (including CAs) that are administered in blood strongly interact with plasma 
proteins through association and dissociation processes, until an equilibrium is reached. On 
glomerular filtration, which is one of the most important metabolic pathways, only CAs in a 
dissociated state can be excreted. Accordingly, the difference in the affinity of chiral dendrimer 
Gd-MRI CAs for plasma proteins affects their metabolism, and could result in differences in body 
distribution, i.e., pharmacokinetics. In this study, the evaluation of CAs by in vivo MRI was 
consistent with the estimation of CAs by in vitro QCM, and QCM offers a highly useful and precise 
method for investigating the biocompatibility of CAs in vitro. 
4. Conclusions/Outlook 
In conclusion, novel chiral dendrimer-triamine-coordinated 2nd- and 3rd-generation Gd-MRI 
CAs, 2-(R), 2-(S), 3-(R), and 3-(S), were synthesized with high optical purity. The pharmacokinetics 
of these chiral dendrimer Gd-MRI CAs were then evaluated by in vivo MRI and estimated by  
in vitro QCM. 
As a result, the r1 values of chiral dendrimer Gd-MRI CAs were almost 4 times higher than  
that of clinically used Gd-DTPA. None of the chiral dendrimer Gd-MRI CAs showed any 
cytotoxicity at a concentration of 0.25 mmol/L. By in vivo MRI, all of the chiral dendrimer Gd-MRI 
CAs circulated in a mouse body for a long time without accumulation in specific organs, and 3-(S) 
Figure 7. Frequency change of the Au electrodes on quartz crystals coated with BSA after addition of
(a) 2-(R) (#) and 2-(S) (4); (b) 3-(R) (#) and 3-(S) (4).
Table 2. Association constant (Ka) of synthesized CAs (2-(R), 2-(S), 3-(R) and 3-(S)) with bovine serum
albu in (BSA).
Sample Kd (mol/L) Ka (mol/L´1) ∆Fmax
2-(R) 1.42 ˆ 10´9 7.04 ˆ 108 13.7
2-(S) 2.49 ˆ 10´11 4.02 ˆ 1010 58.3
3-(R) 1.02 ˆ 10´9 9.80 ˆ 108 969
3-(S) 5.57 ˆ 10´11 1.80 ˆ 1010 83.8
Generally, drugs (including CAs) that are administered in blood strongly interact with
plasma proteins through association and dissociation processes, until an equilibrium is reached.
On glomerular filtration, which is one of the most important metabolic pathways, only CAs in
a dissociated state can be excreted. Accordingly, the difference in the affinity of chiral dendrimer
Gd-MRI CAs for plasma proteins affects their metabolism, and could result in differences in body
distribution, i.e., pharmacokinetics. In this study, the evaluation of CAs by in vivo MRI was consistent
with the estimation of CAs by in vitro QCM, and QCM offers a highly useful and precise method for
investigating the biocompatibility of CAs in vitro.
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4. Conclusions/Outlook
In conclusion, novel chiral dendrimer-triamine-coordinated 2nd- and 3rd-generation Gd-MRI
CAs, 2-(R), 2-(S), 3-(R), and 3-(S), were synthesized with high optical purity. The pharmacokinetics
of these chiral dendrimer Gd-MRI CAs were then evaluated by in vivo MRI and estimated by
in vitro QCM.
As a result, the r1 values of chiral dendrimer Gd-MRI CAs were almost 4 times higher than that
of clinically used Gd-DTPA. None of the chiral dendrimer Gd-MRI CAs showed any cytotoxicity at
a concentration of 0.25 mmol/L. By in vivo MRI, all of the chiral dendrimer Gd-MRI CAs circulated
in a mouse body for a long time without accumulation in specific organs, and 3-(S) was retained
longer in the blood than 3-(R). These results correspond to the affinity of these compounds for plasma
proteins such as BSA, as shown by QCM measurements.
Consequently, the size and generation of dendrimer Gd-MRI CAs strongly affect their retention
in blood and circulation in the body, while the chirality of dendrimer Gd-MRI CAs influenced their
affinity for plasma proteins such as BSA, as shown by in vitro QCM measurements. The present
study, which combined the use of MRI with QCM, could open doors to the synthesis, analysis, and
application of novel chiral dendrimer Gd-MRI CAs with high resolution and performance. Hopefully,
the present study can also help to reduce the dose of Gd-MRI CAs, which could improve patients’
quality of life (QOL).
Acknowledgments: This work was partly supported by the Creation of Innovation Centers for Advanced
Interdisciplinary Research Areas Program “Innovative Techno-Hub for Integrated Medical Bio-imaging” from
the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. Yuka Miyake acknowledges
a fellowship from the Japan Society for the Promotion of Science (JSPS) and financial support from a Grant-in-Aid
for JSPS Fellows (No. 25.5096). Yu Kimura acknowledges financial support from JSPS KAKENHI (Grant No.
25870359). Teruyuki Kondo acknowledges financial support from JSPS KAKENHI (Grant Nos. 15K01819 and
15H01403), Magnetic Health Science Foundation, and SEI Group CSR Foundation. The authors have a patent
application (WO/2009/069833) on part of this work.
Author Contributions: Yuka Miyake, Syungo Ishikawa, Yu Kimura, Aoi Son, Hisatsugu Yamada, Akio
Toshimitsu and Teruyuki Kondo conceived and designed the experiments; Yuka Miyake, Syungo Ishikawa and
Yu Kimura conducted the experiments and analyzed the obtained data; Hirohiko Imai and Tetsuya Matsuda
contributed to the MRI experiments; Yuka Miyake, Yu Kimura and Teruyuki Kondo wrote the manuscript.
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Bammer, R.; Skare, S.; Newbould, R.; Liu, C.; Thijs, V.; Ropele, S.; Clayton, D.B.; Krueger, G.; Moseley, M.E.;
Glover, G.H. Foundations of advanced magnetic resonance imaging. NeuroRx 2005, 2, 167–196. [CrossRef]
[PubMed]
2. Edelman, R.R.; Warach, S. Magnetic resonance imaging (Second of Two Parts). N. Engl. J. Med. 1993, 328,
785–791. [CrossRef] [PubMed]
3. Edelman, R.R.; Warach, S. Magnetic resonance imaging (First of Two Parts). N. Engl. J. Med. 1993, 328,
708–716. [CrossRef] [PubMed]
4. Bottrill, M.; Kwok, L.; Long, N.J. Lanthanides in magnetic resonance imaging. Chem. Soc. Rev. 2006, 35,
557–571. [CrossRef] [PubMed]
5. Pierre, V.C.; Allen, M.J.; Caravan, P. Contrast agents for MRI: 30+ years and where are we going? J. Biol.
Inorg. Chem. 2014, 19, 127–131. [CrossRef] [PubMed]
6. Caravan, P.; Ellison, J.J.; McMurry, T.J.; Lauffer, R.B. Gadolinium(III) chelates as MRI contrast agents:
Structure, dynamics, and applications. Chem. Rev. 1999, 99, 2293–2352. [CrossRef] [PubMed]
7. Hermann, P.; Kotek, J.; Kubícek, V.; Lukes, I. Gadolinium(III) complexes as MRI contrast agents: Ligand
design and properties of the complexes. Dalton Trans. 2008, 9226, 3027–3047. [CrossRef] [PubMed]
8. Werner, E.J.; Datta, A.; Jocher, C.J.; Raymond, K.N. High-relaxivity MRI contrast agents: Where
coordination chemistry meets medical imaging. Angew. Chem. Int. Ed. 2008, 47, 8568–8580. [CrossRef]
[PubMed]
31984
Sensors 2015, 15, 31973–31986
9. Saslow, D.; Boetes, C.; Burke, W.; Harms, S.; Leach, M.O.; Lehman, C.D.; Morris, E.; Pisano, E.; Schnall, M.;
Sener, S.; et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to
mammography. CA Cancer J. Clin. 2007, 57, 75–89. [CrossRef] [PubMed]
10. Boros, E.; Gale, E.M.; Caravan, P. MR imaging probes: Design and applications. Dalton Trans. 2015, 44,
4804–4818. [CrossRef] [PubMed]
11. Perazella, M.A. How should nephrologists approach gadolinium-based contrast imaging in patients with
kidney disease? Clin. J. Am. Soc. Nephrol. 2008, 3, 649–651. [CrossRef] [PubMed]
12. Perazella, M.A. Current status of gadolinium toxicity in patients with kidney disease. Clin. J. Am. Soc.
Nephrol. 2009, 4, 461–469. [CrossRef] [PubMed]
13. Daftari Besheli, L.; Aran, S.; Shaqdan, K.; Kay, J.; Abujudeh, H. Current status of nephrogenic systemic
fibrosis. Clin. Radiol. 2014, 69, 661–668. [CrossRef] [PubMed]
14. Perazella, M.A. Gadolinium-contrast toxicity in patients with kidney disease: Nephrotoxicity and
nephrogenic systemic fibrosis. Curr. Drug Saf. 2008, 3, 67–75. [CrossRef] [PubMed]
15. Weller, A.; Barber, J.L.; Olsen, O.E. Gadolinium and nephrogenic systemic fibrosis: An update. Pediatr. Nephrol.
2014, 29, 1927–1937. [CrossRef] [PubMed]
16. Bumb, A.; Brechbiel, M.W.; Choyke, P. Macromolecular and dendrimer-based magnetic resonance contrast
agents. Acta Radiol. 2010, 51, 751–767. [CrossRef] [PubMed]
17. Kobayashi, H.; Brechbiel, M.W. Nano-sized MRI contrast agents with dendrimer cores. Adv. Drug Deliv. Rev.
2005, 57, 2271–2286. [CrossRef] [PubMed]
18. Langereis, S.; Dirksen, A.; Hackeng, T.M.; van Genderen, M.H.P.; Meijer, E.W. Dendrimers and magnetic
resonance imaging. New J. Chem. 2007, 31, 1152–1155. [CrossRef]
19. Villaraza, A.J.L.; Bumb, A.; Brechbiel, M.W. Macromolecules, dendrimers, and nanomaterials in magnetic
resonance imaging: The interplay between size, function, and pharmacokinetics. Chem. Rev. 2010, 110,
2921–2959. [CrossRef] [PubMed]
20. Astruc, D.; Boisselier, E.; Ornelas, C. Dendrimers designed for functions: From physical, photophysical,
and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and
nanomedicine. Chem. Rev. 2010, 110, 1857–1959. [CrossRef] [PubMed]
21. Campagna, S.; Ceroni, P.; Puntoriero, F. Designing Dendrimers; John Wiley & Sons: Hoboken, NJ, USA, 2011.
22. Vögtle, F.; Richardt, G.; Werner, N. Dendrimer Chemistry; Wiley-VCH: Weinheim, Germany, 2009.
23. Bryant, L.H.; Brechbiel, M.W.; Wu, C.; Bulte, J.W.; Herynek, V.; Frank, J.A. Synthesis and relaxometry of
high-generation (g = 5, 7, 9, and 10) PAMAM dendrimer-dota-gadolinium chelates. J. Magn. Reson. Imaging
1999, 9, 348–352. [CrossRef]
24. Kojima, C.; Turkbey, B.; Ogawa, M.; Bernardo, M.; Regino, C.A.; Bryant, L.H., Jr.; Choyke, P.L.;
Kono, K.; Kobayashi, H. Dendrimer-based MRI contrast agents: The effects of pegylation on relaxivity
and pharmacokinetics. Nanomedicine 2011, 7, 1001–1008. [CrossRef] [PubMed]
25. Labieniec, M.; Watala, C. PAMAM dendrimers—Diverse biomedical applications. Facts and unresolved
questions. Cent. Eur. J. Biol. 2009, 4, 434–451. [CrossRef]
26. Wiener, E.C.; Brechbiel, M.W.; Brothers, H.; Magin, R.L.; Gansow, O.A.; Tomalia, D.A.; Lauterbur, P.C.
Dendrimer-based metal chelates: A new class of magnetic resonance imaging contrast agents. Magn. Reson.
Med. 1994, 31, 1–8. [CrossRef] [PubMed]
27. Kobayashi, H.; Kawamoto, S.; Star, R.A.; Waldmann, T.A.; Brechbiel, M.W.; Choyke, P.L. Activated clearance
of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chase. Bioconjug. Chem.
2003, 14, 1044–1047. [CrossRef] [PubMed]
28. Kukowska-Latallo, J.F.; Candido, K.A.; Cao, Z.; Nigavekar, S.S.; Majoros, I.J.; Thomas, T.P.; Balogh, L.P.;
Khan, M.K.; Baker, J.R., Jr. Nanoparticle targeting of anticancer drug improves therapeutic response in
animal model of human epithelial cancer. Cancer Res. 2005, 65, 5317–5324. [CrossRef] [PubMed]
29. Langereis, S.; de Lussanet, Q.G.; van Genderen, M.H.P.; Backes, W.H.; Meijer, E.W. Multivalent
contrast agents based on gadolinium-diethylenetriaminepentaacetic acid-terminated poly(propylene
imine) dendrimers for magnetic resonance imaging. Macromolecules 2004, 37, 3084–3091. [CrossRef]
30. Wiener, E.C.; Auteri, F.P.; Chen, J.W.; Brechbiel, M.W.; Gansow, O.A.; Schneider, D.S.; Belford, R.L.;
Clarkson, R.B.; Lauterbur, P.C. Molecular dynamics of ion-chelate complexes attached to dendrimers. J. Am.
Chem. Soc. 1996, 118, 7774–7782. [CrossRef]
31985
Sensors 2015, 15, 31973–31986
31. Miyake, Y.; Kimura, Y.; Ishikawa, S.; Tsujita, H.; Miura, H.; Narazaki, M.; Matsuda, T.; Tabata, Y.; Yano, T.;
Toshimitsu, A.; et al. Synthesis and functional evaluation of chiral dendrimer-triamine-coordinated Gd
complexes as highly sensitive MRI contrast agents. Tetrahedron Lett. 2012, 53, 4580–4583. [CrossRef]
32. Miyake, Y.; Kimura, Y.; Orito, N.; Imai, H.; Matsuda, T.; Toshimitsu, A.; Kondo, T. Synthesis and functional
evaluation of chiral dendrimer-triamine-coordinated Gd complexes with polyaminoalcohol end-groups as
highly sensitive MRI contrast agents. Tetrahedron 2015, 71, 4438–4444. [CrossRef]
33. Fee, C.J. Label-free, real-time interaction and adsorption analysis 2: Quartz crystal microbalance. In Protein
Nanotechnology, 2nd ed.; Gerrard, J.A., Ed.; Springer: New York, NY, USA, 2013; pp. 313–322.
34. Sauerbrey, G. Use of quartz crystal vibrator for weighting thin films on a microbalance. Z. Phys. 1959, 155,
206–222. [CrossRef]
35. Guyton, A.C.; Hall, J.E. The kidneys and body fluids (Unit V), The body fluid compartments: Extracellular
and intracellular fluids; Interstitial fluid and edema (Chapter 25). In Textbook of Medical Physiology, 10th ed.;
W.B. Saunders Company: Philadelphia, PA, USA, 2000; pp. 264–278.
36. Chaudhuri, P.; Wieghardt, K. The chemistry of 1,4,7-triazacyclononane and related tridentate macrocyclic
compounds. Prog. Inorg. Chem. 1987, 35, 329–436.
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open
access article distributed under the terms and conditions of the Creative Commons by
Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
31986
